OncoSec Medical names new CFO/COO

16 July 2018

OncoSec Medical (Nasdaq: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Sara Bonstein as Chief Financial Officer and Chief Operating Officer.

In these roles, Ms Bonstein will be responsible for leading the company's financial and capital markets activities, as well as overseeing all G&A functions and technical operations. She will succeed current CFO Richard Slansky, who will leave to pursue new opportunities.

"Sara is a seasoned strategic executive with significant experience in the public biotechnology and pharmaceutical industry," said Daniel O'Connor, president and chief executive of OncoSec, adding: "She joins OncoSec at an extremely important time, as we look to achieve several key milestones in the remainder of 2018. Sara has a proven track record of success and I am pleased she chose to join OncoSec."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK